Primary Regulatory Sources
Reliable references are essential for a prescription-medicine website because indications, dosing, warnings, and product formulations can change. The principal sources used for this Ibrutinib site are the current U.S. prescribing information, the U.S. DailyMed record for IMBRUVICA, and the European Medicines Agency’s Imbruvica EPAR and product information. These sources provide a stronger foundation than unsourced commercial descriptions.
U.S. FDA Prescribing Information
The U.S. Food and Drug Administration prescribing information is the primary source for current U.S. labeled indications, dosage, dosage forms, warnings, precautions, interactions, and other prescribing details. The 2025 label identifies ibrutinib as a kinase inhibitor and lists CLL/SLL, CLL/SLL with 17p deletion, WM, and cGVHD as labeled indications in the United States.
DailyMed
DailyMed provides the U.S. structured labeling record. Its current IMBRUVICA entry identifies capsules, tablets, and oral suspension and gives the dosage forms and strengths. It also presents the administration instructions and warning sections. DailyMed is useful for checking the structured label text and product presentation information.
European Medicines Agency
The European Medicines Agency’s Imbruvica EPAR is important for understanding EU authorization. The current EMA page identifies ibrutinib as the active substance and describes treatment settings for CLL, MCL, and WM under the European authorization. The EMA record also identifies Janssen-Cilag International NV as the marketing authorization holder for the EU product.
Clinical Literature
Clinical literature can provide context beyond the label, but it should be interpreted carefully. A trial result applies to the studied population and treatment strategy; it does not guarantee the same outcome for every patient. When scientific literature and regulatory labeling are used together, the website should distinguish established approved use from investigational or historical evidence.
Product-Specific Documentation
The supplied product information for this site identifies Ibruxen 140 mg with Everest and Ibrucent 140 mg with Incepta. Because the website brief does not provide independent product authorization documents for those brands, the site should not invent citations claiming manufacturing sites, regulatory approvals, certificates, or corporate relationships that have not been verified.
Why Source Quality Matters
Reference quality also matters for safety. Drug-interaction information, reproductive warnings, bleeding precautions, and dose-modification instructions should be checked against the latest applicable label. Secondary websites can become outdated, so readers should be directed to regulatory documents when a clinical decision is involved.
How to Use the References
Readers can use the references page as a navigation guide: FDA and DailyMed for U.S. prescribing information; EMA for EU authorization and product information; and peer-reviewed literature or recognized clinical organizations for broader evidence context. The goal is transparent sourcing rather than citation volume. A small number of authoritative, current references is more useful than a long list of weak or unrelated sources.
Additional Practical Context
A reference list is more useful when readers understand what each source is designed to answer. Regulatory labels are strongest for approved indications, dosing, warnings, and dosage forms. The EMA EPAR is useful for European authorization and assessment information. DailyMed provides structured U.S. labeling. Peer-reviewed studies can explain clinical evidence and pharmacology but may describe populations or treatment strategies that differ from current approved use. The website should therefore cite sources in context and avoid treating a single paper or commercial page as a universal authority.
Further Practical Context
Sources should be revisited periodically because regulatory documents have dates and revision histories. A page based on an older label can remain accurate for some background facts while becoming outdated for dosing, indications, or safety warnings. For this reason, the website should display the source title and, where practical, the relevant update date. Readers should also understand that a U.S. source and an EU source answer different regulatory questions. The existence of an EU authorization does not automatically establish authorization in another country. Reference quality is therefore about both authority and applicability.
Editorial Note
The most authoritative source depends on the question. Regulatory labels are usually the starting point for current approved use, while scientific literature provides additional evidence and context.
Related Information
Readers can continue to the site’s related pages on About Ibrutinib, Clinical Information, How Ibrutinib Works, Uses & Treatment, Dosage & Administration, Safety Information, Side Effects, Product Verification, and References.